NanoViricides Inc (NYSEAMERICAN:NNVC) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totalling 373,400 shares, a drop of 10.3% from the June 30th total of 416,300 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily volume of 119,000 shares, the short-interest ratio is presently 3.1 days.
NanoViricides stock opened at $0.24 on Friday. NanoViricides has a 1-year low of $0.20 and a 1-year high of $0.68.
NanoViricides (NYSEAMERICAN:NNVC) last released its earnings results on Wednesday, May 15th. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03).
NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate.
Featured Article: Street Name
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.